# Ziihera (zanidatamab-hrii)

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/ziihera-zanidatamab-hrii
Canonical HTML page: https://getbiobrief.com/entity/ziihera-zanidatamab-hrii

## Timeline

- **2026-Q4**: Anticipated Regulatory Milestones — Potential for further regulatory filings based on ongoing Phase 3 data.
- **2026-04-20**: AACR Annual Meeting — Expected dates for the 2026 AACR meeting where Ziihera data will be showcased.
- **2026-03-18**: Presentation Announcement — Zymeworks announces multiple abstracts accepted for AACR 2026.

## Recent coverage (1 stories)

### Zymeworks to Present Key Ziihera Clinical Data at 2026 AACR Annual Meeting
2026-03-18 13:15:18 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Zymeworks Inc. (ZYME) has announced multiple upcoming presentations for its lead asset, Ziihera (zanidatamab-hrii), at the 2026 AACR Annual Meeting. These presentations are expected to showcase the therapeutic's efficacy and safety across various HER2-expressing cancers, reinforcing its position in the competitive oncology landscape.
Full story: https://getbiobrief.com/story/zymeworks-ziihera-aacr-2026-presentations

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.